KTN and UKRI Release Medicines Manufacturing Impact Report
Take a look at our recently released report which highlights the significant impact made through investment and collaboration into UK Medicines Manufacturing.
The Medicines Manufacturing Challenge was established in 2017 to support and grow the UK’s capabilities in manufacturing medicines. As of July 2021, £255 million has been invested in developing first-of-a-kind technologies to manufacture medicines and accelerate patient access to new drugs and treatments, firmly establishing the UK as a leading global hub for the development, production and delivery of cutting-edge therapies.
UKRI investment in the Medicines Manufacturing Challenge has driven innovation in medicines manufacturing, de-risked development of new technologies, supported infrastructure and embedded a culture of collaboration and fresh ideas across the UK life sciences landscape. It has also helped to establish the skills and capabilities required to deliver the next generation of therapies through training opportunities and apprenticeships.
A successful medicines manufacturing sector depends on a connected ecosystem, and KTN is proud to support the sector through the Medicines Manufacturing Challenge Community, helping innovative organisations work together to advance the UK’s medicines manufacturing capabilities.
KTN continues to invest in the whole breadth of the Medicines Manufacturing Challenge Community, forming partnerships, championing innovation and shaping future solutions.
If you’d like to find out more, please contact Karen Wilkinson.